Literature DB >> 19249520

Model for end-stage liver disease: impact of the new deceased donor liver allocation policy in São Paulo, Brazil.

F Monteiro1, S A Coria, R Boni, L A Pereira.   

Abstract

Since 1997, organ transplantation in Brazil has been regulated by a federal law, which was created to guarantee equal access to treatment on a national scale. Centralized deceased donor organ procurement and sharing are controlled by the Health Department of each state of the nation, following a regional allocation policy. In São Paulo, time on the waiting list was the main criterion adopted to allocate deceased donor livers up to July 15, 2006. After that, model for end-stage liver disease/pediatric end-stage liver disease (MELD/PELD) scores were the main criteria. The aim of this study was to investigate the impact of the new criteria on patient survival rates using 895 consecutive liver recipients. The 1-year patient survival rates were compared between recipients transplanted based on the waiting time policy and based on MELD/PELD scores showing similar results (69.79% vs 66.69%; P = NS). Regarding liver allocation based on MELD/PELD scores, worse survival outcomes were observed among recipients transplanted with higher MELD scores. Also, under the new criteria, a high frequency of hepatocellular carcinoma and pediatric recipients underwent transplantation.

Entities:  

Mesh:

Year:  2009        PMID: 19249520     DOI: 10.1016/j.transproceed.2008.09.059

Source DB:  PubMed          Journal:  Transplant Proc        ISSN: 0041-1345            Impact factor:   1.066


  2 in total

1.  Living donor liver transplantation for high model for end-stage liver disease score: What have we learned?

Authors:  Hany Dabbous; Mohammad Sakr; Sara Abdelhakam; Iman Montasser; Mohamed Bahaa; Hany Said; Mahmoud El-Meteini
Journal:  World J Hepatol       Date:  2016-08-08

2.  Impact of MELD allocation policy on survival outcomes after liver transplantation: a single-center study in northeast Brazil.

Authors:  Thales Paulo Batista; Bernardo David Sabat; Paulo Sérgio V Melo; Luiz Eduardo C Miranda; Olival Cirilo L Fonseca-Neto; Américo Gusmão Amorim; Cláudio Moura Lacerda
Journal:  Clinics (Sao Paulo)       Date:  2011       Impact factor: 2.365

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.